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1. Introduction 
Laboratory diagnosis of acute leukemia in modern hematology practice is increasingly 
relying on guidelines that require the availability of relatively expensive machines with 
consistent need for continuous quality control, kits supply and maintenance. 
In under-resourced hematology laboratories there is usually a missing step in the battery of 
required investigations. Moreover, when some of the advanced diagnostic instruments can 
be found then the problem of chronic inadequate and irregular supply of kits and services 
would supervene. Therefore, the laboratory diagnosis would mostly depend on the more 
basic, but consistently available and well controlled, laboratory techniques that should at 
least include complete blood count (CBC) and peripheral blood morphology, after which a 
bone marrow study with aspirate and sometimes a trephine biopsy will follow. 
Moreover, in specialized hematology centers there may be a routine availability of few 
special stains, a very limited immunophenotyping CD markers panel, cytogenetics and PCR 
or FISH testing mostly for BCR-ABL1 oncogene. 
The aim of diagnosis, lineage assignment and sub-classification of acute leukemia in these 
laboratories should immediately serve a clear therapeutic goal. 
Sketching rational systematic schemes for optimum use of the locally available investigation 
options would usually permit the diagnosis of most varieties of acute leukemias with a very 
acceptable level of reliability. Also these schemes may provide invaluable information 
regarding the prospect of update and future plans for laboratory development as it can 
show clearly where the weak joints are (Abdulsalam, 2010). 
2. Basis of diagnosis of myelodysplastic syndrome (MDS) 
The WHO classification of this pre-AML disorder (Table 1) can be applied in most under-
resourced laboratories as it only entails the use of peripheral blood morphology and bone 
marrow aspirate morphology with Perl’s reaction (diagnosis of rare hypoplastic and 
myelofibrotic MDS would require also bone marrow trephine biopsy) with the sole addition 
of cytogenetics, preferably performed on marrow aspirate sample. 
Even when cytogenetic testing is not available, still the WHO classification can be reliably 
applied for the diagnosis of most of the MDS subcategories, with the exceptions of the 
otherwise provisional diagnosis of MDS-5q- syndrome (which is characteristically found in a 
middle age or an elderly female with  peripheral blood macrocytic anemia and upper 
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Type Peripheral blood Bone marrow aspirate 
Refractory cytopenia with 
unilineage dysplasia: 
- Refractory anemia (RA) 
- Refractory neutropenia 
- Refractory 
thrombocytopenia 
Uni- or bi-cytopenia 
and <1% blasts 
Unilineage dysplasia* with <5% blasts 
Refractory anemia with ring 
sideroblasts (RARS) 
Anemia and <1% 
blasts 
Erythroid dysplasia only with <5% 
blasts and >15% ring sideroblasts 
Refractory cytopenia with 
multilineage dysplasia 
Bi- or pan-cytopenia 
and <1% blasts 
Bi- or tri-dysplasia with <5% blasts 
and <15% ring sideroblasts 
Refractory cytopenia with 
multilineage dysplasia and 
ring sideroblasts 
Bi- or pan-cytopenia 
and <1% blasts 
Bi- or tri-dysplasia with <5% blasts 
and >15% ring sideroblasts 
Refractory anemia with excess 
blasts-1 (RAEB-1) 
1-4% blasts 5-9% blasts and no Auer rods 
Refractory anemia with excess 
blasts-2 (RAEB-2) 
5-19% blasts 
10-19% blasts, or <19% blasts plus 
Auer rods** 
MDS-Unclassified 
Uni-, bi- or pan-
cytopenia and <1% 
blasts 
Cytogenetic diagnosis of MDS with 
uni-, bi- or tri-lineage dysplasia in 
<10% of the cells and <5% blasts 
Isolated 5q- syndrome 
Anemia with upper 
normal or increase 
platelet count 
Isolated del(5q) on cytogenetic study, 
prominent large megakaryocytes with 
hypolobated nuclei and <5% blasts*** 
* Dysplasia is considered significant only if it is present in >10% of the cells. 
** If Auer rods or pseudo-Chediak Higashi inclusions are present then MDS RAEB-2 is diagnosed even 
when the peripheral blood and bone marrow blasts are <5% and <10% respectively. 
*** If blasts > 5% then it is classified as RAEB, although still lenalidomide treatment should be tried. 
Table 1. WHO classification of MDS, 2008 (Vardiman, et al, 2009) 
normal platelet count or even thrombocytosis, bone marrow megakaryocytes of normal 
overall size but with a relatively small mono- or bi-lobed nucleus and a very good response 
to a therapeutic trial of lenalidomide) (Kelaidi et al, 2008) and MDS-Unclassified (which can 
be diagnosed on follow up when the disease persists or even progress). This classification, 
unlike the late FAB classification, would keep with the newest 20% blasts cut-off point to 
diagnose acute leukemia, coping with the worldwide standards of MDS literatures and 
provide much more relevant prognostic groups. 
3. Diagnosis of acute leukemia in under-resourced laboratories 
FAB classification (Table 2) of acute leukemia should be applied in under-resourced 
laboratories where the only available routine techniques for diagnosis are morphology and 
special stains (Abdulsalam, 2010). The scheme in (Figure 1) may be used as a general 
guideline for the diagnosis of acute leukemia in under-resourced laboratories; however, it 
should be modified to optimally fit into the locally available techniques. 
The practical application of WHO classification for acute leukemia (Tables 3 and 4) requires 
both diagnosis and risk stratification. The diagnosis can be based on morphology, special 
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stains and immunophenotyping (preferably using flowcytometry, or if it is not available 
then one can rely on either immunocytochemistry with/without immunohistochemistry). 
Laboratory risk stratification relies on cytogenetics and multiplex conventional PCR. 
Later on, a follow up for minimal residual disease can be performed using the same genetic 
abnormality found at diagnosis, i.e., cytogenetic remission, or more accurately, real time 
quantitative (RQ) PCR for quantization of the characteristic translocation that was found 
positive (but without quantization using conventional “qualitative” PCR) at diagnosis. 
 
Acute 
leukemia 
Subtype Morphology Additional tests 
ALL 
L1 
Small, homogeneous with 
high N:C ratio blasts 
TdT, CD3, CD79a, CD20, CD10 
L2 
Larger, heterogeneous, 
nucleolated with low N:C 
ratio blasts 
Leukemic phase 
of Burkitt’s 
lymphoma (L3)
Large, homogeneous and 
nucleolated blasts with 
basophilic and vacuolated 
cytoplasm 
Cytogenetics, ISH or PCR 
AML 
M0 Undifferentiated blasts 
Anti-MPO, CD117, CD33, CD68 
or Lysozyme 
M1 
Undifferentiated blasts ± 
dysplastic myeloid 
differentiation 
SBB stain 
M2 
Myeloblasts with myeloid 
maturation 
M3 
Characteristic morphology, 
Faggot cells 
M3 variant 
Characteristic morphology, 
bilobed nuclei 
M4 
Peripheral blood monocytes 
≥5.0 *109/l ± bone marrow 
monocytic lineage ≥20% 
NSE confirmation of monocytic 
lineage 
M5a 
(Monoblastic), 
M5b (Monocytic) 
and M5c 
(Histiocytic) 
Bone marrow monocytic 
lineage ≥80% 
M6 
Trilineage dysplasia and 
>50% erythroblasts 
SBB, Glycophorin + anti-MPO, 
avoid CD34 as it would stain 
both myeloblasts and 
proerythroblasts 
M7 
Blast with cytoplasmic blebs 
and bone marrow fibrosis 
CD41 
Table 2. Diagnosis of acute leukemia based on FAB groups 
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Follow up for minimal residual disease using a multi-color flowcytometry can be adequately 
performed (Thorn et al, 2011) but is usually more demanding than the genetic techniques, 
and therefore, it may not be the best choice in a resource-poor laboratory. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute leukemia 
≥ 20 blast cells of total or non-
erythroid bone marrow cells 
Clinical features, 
Romanowsky and 
special stains 
morphology 
Undifferentiated acute 
leukemia: Therapeutic 
trial for ALL 
AML 
Romanowsky stain: M2, 
M3, M4, M5b, M5c & M6 
SBB: M1, M3v 
M3v: Therapeutic trial 
NSE: M5a 
Anti-MPO: M0 
CD41: M7 
ALL Romanowsky stain: 
L1, L2 and L3 
SBB: Negative 
PAS: cALL 
TdT: positive in L2 and 
negative in leukemic phase 
of lymphoma including L3, 
which is positive for sIg 
L2: Therapeutic trial 
T-ALL: 
cCD3 
B-ALL: CD79a 
A
d
u
lt
 
CD20 IHC 
BCR-ABL1 oncogene: PCR or FISH 
Clinical, 
radiological 
and IHC 
CD1a and sCD3 
CD10 and cIg 
L1: Start chemotherapy 
 
Fig. 1. Options for diagnosis of acute leukemia in resource-poor laboratories: FAB-based 
classification serving a clear therapeutic target. 
3.1 Basis of diagnosis of acute leukemia 
In the WHO classification of acute leukemia (Jaffe, et al, 2001) the diagnosis is based on an 
arbitrary cut-off point of 20% blasts as a percentage of bone marrow total or non-erythroid 
cells or as a percentage of peripheral blood cells. This exact percent is also applied 
nowadays in under-resourced laboratories were the FAB classification should be used (Bain, 
2010a). 
This 20% myeloblasts cut-off point seems to be universally accepted and for the time being it 
represents the best known tool for defining acute leukemia. However, the word “arbitrary” 
may still precede it and this may be attributed to (Abdulsalam, 2011): 
1. This precise percent does not represent some specific biological event in the continuum 
of increasing blast count, but it is merely, to the best to our current knowledge, a cut-off 
point that permits a relatively clear classification and therapeutic aim. However, the fact 
that some high risk MDS patients are being treated actively with only 10% bone 
marrow blasts should be remembered. 
www.intechopen.com
 Diagnosis of Acute Leukemia in Under-Resourced Laboratories 
 
23 
 
--- Therapy- related myeloid neoplasms 
--- De novo myeloid neoplasms 
- AML with recurrent genetic abnormalities including 
t(8;21)(q22;q22); RUNX1–RUNX1T1 
inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB–MYH11 
t(15;17)(q22;q12); PML–RARA 
t(9;11)(p22;q23); MLLT3–MLL 
t(6;9)(p23;q34); DEK–NUP214 
inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1–EVI1 
t(1;22)(p13;q13); RBM15–MKL1 
Provisional entity: AML with mutated NPM1 
Provisional entity: AML with mutated CEBPA 
- AML with myelodysplasia-related changes 
- AML not otherwise categorized 
- Myeloid sarcoma 
- Myeloid proliferation related to Down syndrome 
- Transient abnormal myelopoiesis 
- Myeloid leukemia associated with Down syndrome 
- Blastic plasmacytoid dendritic cell neoplasm 
Table 3. WHO classification of AML, 2008 (Vardiman, et al, 2009) 
 
 
--- B lymphoblastic leukemia/lymphoma 
- B lymphoblastic leukemia/lymphoma, not otherwise specified 
- B lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities including 
t(9;22)(q34;q11.2) and BCR–ABL1 
translocation involving 11q23 and MLL rearrangement 
t(12;21)(p13;q22) and ETV6–RUNX1 
hyperdiploidy (> 50 chromosomes) 
hypodiploidy (< 46 chromosomes) 
t(5;14)(q31;q32) and IL3–IGH 
t(1;19)(q23;p13.3) and TCF3–PBX1 
--- T lymphoblastic leukemia/lymphoma 
Table 4. WHO classification of ALL, 2008 (Vardiman, et al, 2009) 
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2. The significant difference in the cut-off point of blast percent between peripheral blood 
and bone marrow is well established in MDS as the two groups RAEB-1 (blast count 
less than 5% in peripheral blood and 5-9% in bone marrow) and RAEB-2 (blast count 5-
9% in peripheral blood and 10-19% in bone marrow). In acute leukemia no such 
discrimination is available. 
3. The morphological finding of pathological “clonal” blast, type II that contains Auer 
rods, Pseudo-Chédiak-Higashi (Abdulsalam & Sabeeh, 2011) (Image 1) or other specific 
inclusions that are not seen in reactive marrow, is referring to the diagnosis of RAEB-2 
or AML, here again the arbitrary cut-off point of 20% blasts will decide the specific 
diagnosis. 
4. The original FAB classification was based for many years on the arbitrary cut-off point of 
30% bone marrow blasts and previously some patients with 20-29% blasts remained stable 
over months without chemotherapy. However, this major percent change was driven by 
the survival studies which revealed that patients with 20-29% myeloblasts have a similar 
survival pattern as those with 30% and more in the bone marrow (Jaffe et al, 2001). 
5. Although myeloblasts recognition criteria as agranular and granular blasts achieved a 
reasonable consensus, there are minor discordances in their definitions and in practice it 
may be a matter of convention (subjective method) to discriminate it from the 
continuum of cells, as in deciding whether this cell is a blast type III or a promyelocyte. 
6. The “blasts” refer to myeloblasts, lymphoblasts, monoblasts, promonocytes and 
megakaryoblasts. 
7. Diagnosis of AML-M3 and its variant is not related to the blast percent. 
8. Cases with blast cells less than 20% may still be diagnosed as acute leukemia if they 
present with certain recurrent cytogenetic abnormalities as in AML M4 with inv(16) or 
t(16;16)(p13;q22) and AML M2 with t(8;21) (Jaffe et al, 2001). 
9. The utilization of 20% lower blast threshold is not really an issue in ALL because most 
patients at diagnosis already have more than 50% blasts. Moreover, a patient with 
normal or reduced peripheral blood count and bone marrow lymphoblasts about or 
slightly above 20% would usually be classified as lymphoblastic lymphoma rather than 
ALL. A 25% cut-off point has been suggested to arbitrarily differentiate between the 
two conditions. 
10.  In AML-M0 and M1 the 20% blasts cut-off point is also of no use in practice. 
Laboratory diagnosis of acute leukemia in modern hematology practice is increasingly 
relying on objective techniques to detect a specific ultrastructural or genetic abnormality. 
Therefore, the era of 20% blasts to diagnose acute leukemia may not stand the time any 
longer than that of the old FAB group 30% blasts lower threshold. However, at least in the 
present and the near future the morphology will remain the initial diagnostic test of acute 
leukemia and the abovementioned blast threshold will still be useful as a tool for 
classification (Abdulsalam, 2011). 
The presence or absence of myeloblasts has a central role in diagnosis of AML and suspicion 
of ALL respectively. The blasts are divided into agranular (type I) and granular (type II and 
III) blasts based on Romanowsky stain morphology. However, when using SBB stain many 
of the “apparently” agranular blasts turn to be granular. Pathognomonic signs of AML that 
can be seen with Romanowsky stain and more frequently with SBB stain include SBB-
positive granules, Auer rods, atypical “thick” Auer rods, pseudo-Chediak-Higashi 
inclusions (Abdulsalam et al, 2011a) (Image 1) and rectangular crystalline structures (Merino 
& Esteve, 2005) . 
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Image 1. Pseudo-Chédiak-Higashi inclusions together with atypical “thick” Auer rods in 
AML. 
3.2 Clinical features 
At diagnosis, acute leukemia should, in most of the cases, be clinically manifested within the 
last month with non-specific features like lethargy and fatigue or more commonly with 
specific features related to organ infiltration including bone marrow which results in anemia-
related features, infections and bleeding. Other organ infiltration may refer not only to broad 
suspicion of acute leukemia but more likely to lineage assignment or even to a specific 
diagnosis, e.g., hepatosplenomegaly, lymphadenopathy, CNS symptoms and testicular 
involvement are in favor of ALL, severe bone pain in lower extremities would refer to B-ALL, 
thymic mediastinal mass and pleural effusion to T-ALL, bleeding tendency with overt 
coagulation tests defect can refer to AML-M3 and its variant and gum hypertrophy, skin 
involvement and hepatosplenomegaly in M4 and, more commonly, in M5. 
3.3 Complete blood count (CBC) 
Acute leukemia in most of the cases would present with one, or more often more abnormalities 
of the CBC, including anemia, leucocytosis (or less common leucopenia) and thrombocytopenia. 
Even when the WBC count is within normal limits the anemia, thrombocytopenia and WBC 
flags (in most automated cell counters) would raise fair enough suspicion. 
Clinical features combined with CBC should be very sensitive in directing acute leukemia 
cases to be studied by peripheral blood smear. 
3.4 Peripheral blood smear 
Should be the backbone for the diagnosis of acute leukemia when there is leucocytosis or 
when leucocyte count is within reference range, as in most of the cases it provides a specific 
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diagnosis (ALL-L3 and AML-M3), a provisional diagnosis (ALL-L1 and AML M2, M3 
variant, M4, M5b, M5c and M6) or at least a limited differential diagnosis (ALL-L2 and 
AML-M0, M1, M5a and M7). 
When blasts are numerous in peripheral blood then special stains like SBB can be applied 
directly to it, this can be very useful for emergency diagnosis of AML-M3 variant especially 
within short time like before the weekend (Abdulsalam & Sabeeh, 2010). In cases with 
leucopenia, although frank blast cells may not be easily found, still there should be at least a 
clue to the diagnosis (including anemia, thrombocytopenia and myeloid dysplasia). 
The presence of nucleated red cells and myeloid dysplasia mainly in the form of Pelger-
Huet neutrophils should be investigated as the former can refer to AML-M6 and the later 
can suggest an AML with myelodysplasia. A bone marrow study should follow including 
aspirate and biopsy (when there is peripheral blood pancytopenia, and dry tap, 
hypocellular, diluted or difficult aspirate). 
3.5 Bone marrow aspirate (BMA) 
The diagnosis of acute leukemia in many instances is evident from the peripheral blood 
film; however, the bone marrow aspirate examination is always essential for confirmation of 
diagnosis, classification and application of special techniques including cytochemical stains, 
genetic studies, Immunocytochemistry (ICC) and immunohistochemistry (IHC). 
IHC staining can be applied using the clotted marrow aspirate as a regular tissue sample 
after fixation and without decalcification (Bain, 2001a), to avoid bone marrow biopsy when 
there is no need for this procedure apart from the intention to apply immunophenotyping; 
however, it should be noted that the only use of clotted aspirate is for immunophenotyping, 
i.e., it should not be used as a regular morphology sample or any other application. 
Apart from AML-M3 and its variant, the provisional and final diagnosis of the subtype of 
acute leukemia should not be issued before a proper BMA is performed. The classification of 
AML FAB groups is based on the percentages of blasts, maturing myeloid series 
(promyelocytes to neutrophils), monocytic series and erythroblasts from the total nucleated 
marrow cells. Also in some occasions many vital signs may be seen only in marrow aspirate 
like few Faggot cells in AML-M3 variant and even Auer rods. This phenomenon is 
aggravated when there is a peripheral leucopenia. 
Diagnosis of acute leukemia is based on the presence of at least 20% blasts of total nucleated 
marrow cells, this condition may not be applicable especially in some AML cases, then 20% 
blasts limit should be obtained from the non-erythroid non-lymphoid marrow cells, 
otherwise the case would be labelled as MDS (Table 1). The reason for setting two lower 
thresholds is to simplify the morphology counts in practice, where in the first type of 
threshold the hematologist needs only to count the blast cells from all the nucleated cells in 
the field, this is much easier in practice but it would certainly require much higher blast 
threshold (which is available in almost all cases of ALL and many AML patients) than what 
would be required in the second form, which would be much more effort demanding and 
time consuming as one has to exclude erythroblasts, lymphocytes, plasma cells, 
macrophages and mast cells from the count. 
Diagnosis of AML with myelodysplasia can only be confirmed by studying the bone 
marrow aspirate morphology with trilineage dysplasia. Dyserythropoiesis alone can be seen 
in many malignancies and is multifactorial, dysmyelopoiesis is supportive to the diagnosis 
of AML; however in cases where neutrophils and maturing myeloid cells are few then 
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absence of dysmyelopoiesis does not affect the diagnosis. Dysmegakaryopoiesis, especially 
in the form of micromegakaryocytes is in favour of diagnosis of AML with a preceding 
myelodysplastic syndrome. 
3.6 Bone marrow biopsy 
Is indicated when failed to obtain an adequate marrow aspirate, which may result from 
improper aspiration technique, presence of fibrosis (especially in ALL and AML-M7; in both 
conditions there may be a leucoerythroblastic anemia and tear drop poikilocytes in peripheral 
blood), aleukemic or subleukemic peripheral blood and bone marrow aspirate smears due to 
heavily packed marrow (especially in ALL) or presence of hypoplastic acute leukemia 
(especially in AML). It is also indicated when there is an intention to apply routine 
immunophenotyping (although this can be adequately applied on clotted marrow sections, see 
paragraph 3.5). It can be stated that the bone marrow biopsy is not an essential investigation in 
acute leukemia diagnosis when obtaining an adequate marrow aspirate (Bain, 2001b). 
The presence of peripheral blood leucocyte count above or within the upper normal count 
can be used as an indicator that a bone marrow biopsy would not be essential; in contrast, 
leucopenia or pancytopenia suggest the need for bone marrow biopsy. 
3.7 Acute Myeloid Leukemia (AML) 
With Romanowsky stain morphology AML- M2, M3, M4, M5b, M5c and M6 can be 
recognized readily. 
By adding few special stains such as Sudan black B, and not myeloperoxidase (MPO) as SBB 
has a little more sensitivity in detecting myeloblasts which is crucial for diagnosis of AML, 
plus a non-specific esterase (NSE) stain as ANAE it becomes possible to recognize AML-M1 
and most cases of AML-M5a respectively (Bain, 2006). 
Rare types of AML like M5c require a higher degree of morphology experience, in which 
malignant cells appearance is reminiscent of tissue histiocytes (Image 2) (Abdulsalam & 
Sabeeh, 2009a). 
The AML cases that cannot be distinguished by Romanowsky and special stains 
morphology are M0 and M7, for which the presence of myeloid dysplasia (abnormal nuclear 
morphology and cytoplasm hypogranularity using a Romanowsky stain or absence of SBB 
stained granules from maturing myeloid cells and neutrophils) (Image 7) in the former and 
the blasts' cytoplasmic blebs and bone marrow fibrosis in the latter may give a hint for the 
probable diagnosis, however there is still the need for more positive diagnostic technique 
and as the flow cytometry immunophenotyping may not be available then the use of a 
limited number of CD markers study by ICC/IHC is the option, these include mainly anti-
myeloperoxidase for M0 and CD41 for M7. 
When resources are limited then it is for the best to concentrate on cytoplasmic ICC/IHC 
CD markers with the highest lineage sensitivity and specificity. 
There is a small proportion of cases that would be only certainly subclassified after the 
response to treatment as in rare forms of AML-M3v in spite that SBB stain is usually of help 
in this form (Images 5 and 6). 
Risk stratification of AML is based on genetic studies. 
3.8 Acute Lymphoblastic Leukemia (ALL) 
Consideration of clinical as well as hematological features permits a strong presumptive 
diagnosis of ALL (Bain, 2010). ALL-L3 diagnosis (which should be referred to as the 
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Image 2. Blast cells appearance in AML-M5c. 
leukemic phase of Burkitt’s lymphoma as it arises from mature B-cells) would be obvious 
by morphology alone and it is convenient to rely on morphological diagnosis of ALL-L1 
and start treatment. Also if a patient with an acute leukemia showing heterogeneous 
blasts that has no morphological markers of myeloid differentiation, negative staining 
with SBB with unavailability of further differentiating procedures then it may be treated 
initially as ALL-L2, as statistically speaking it would be much more possible than AML-
M0. The negative result in staining with SBB is very helpful, while the addition of the 
special stain PAS would improve the chances of the correct diagnosis of common ALL. 
However, a case with positive staining results for both SBB and PAS is an acute myeloid 
leukemia (Image 3). 
Clinical features as bone pain and radiological sign of mediastinal mass may presumptively 
aid in differentiating between B- and T-ALL, however, using ICC/IHC antibodies including 
CD79a for B lineage and CD3 for T lineage are necessary. After setting the diagnosis of B-
ALL in adults then ICC/IHC CD20 typing and PCR or FISH for BCR-ABL1 fusion gene 
would affect the treatment options. 
In children (neonate up to 15 years) there is some reluctance for BCR-ABL1 testing due to its 
low frequency, only about 3%. However, it may be prudent to test for this transcript in 
children who have some lymphoblasts with large azurophilic granules (represent 
approximately 10% of cases) (Jaffe, et al, 2001) as this, beside cutting short additional costs, 
can offer a safer limit. 
Rare cases of ALL-L2 that are confused with leukemic phase of large cell lymphoma can be 
differentiated through the use of TdT immunohistochemistry typing on bone marrow 
biopsy slide, which would be positive in ALL but not in lymphoma. 
Risk stratification of ALL is based on immunophenotypic and genetic studies. 
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Image 3. Composite photograph of a patient with AML-M1 who had a 95% PAS-positive 
blasts (left image) and SBB positive blasts (right image). 
3.9 Biphenotypic acute leukemia 
The diagnosis of this acute leukemia requires a simultaneous application of several myeloid 
and lymphoid CD markers, or at least a request for the main lymphoid markers (CD3 and 
CD79a) after finding a SBB positive result (Matutes et al, 1997). 
In resource-poor laboratories a step-by-step algorithm is followed in order to use the least 
possible resources, therefore, the identification of a mixed acute leukemia can be missed, as 
when some clinical, morphological, cytochemical or immunological markers refer to one 
diagnosis then the other lines of investigations are usually skipped to save expenses. 
However, misdiagnosis of this rare type of acute leukemia to only one of its components 
may, in some cases, not adversely affect the patient. 
3.10 Rare types of acute leukemia 
In a resource-poor laboratory these types of acute leukemia can be identified only if it 
happened to show some characteristic features using one of the essential techniques 
including, e.g., AML-M5c characteristic peripheral blood and bone marrow morphology, 
while others like biphenotypic acute leukemia may be misdiagnosed to only one of its 
components as described in paragraph 3.9. Natural killer-cell leukemia can be confused 
initially with reactive lymphocytosis as it results in CD3 negative and its characteristic CD56 
marker is not usually tested for in an under-resourced laboratory. 
3.11 Special stains 
For diagnosis of AML, especially M1 and M5, the addition of Sudan black B (SBB) and a 
non-specific esterase stain as α-naphthyl acetate esterase is respectively essential. While for 
ALL a negative result (0-2%, these rare SBB positively stained blasts represent remnant 
normal myeloblasts) with SBB staining is crucial to support the diagnosis. The addition of 
PAS stain would not add a lot to support the diagnosis of ALL as it can, at least occasionally, 
be equally positive in AML; however, a positive PAS stained vacuolated blasts can be useful 
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to refer to cALL in 98% of cases (Bain, 2010a), here again CD10 ICC/IHC staining would be 
more meaningful. 
3.11.1 Sudan Black B (SBB) stain 
It is one of the few, but very useful, cytochemical stains to choose in a resource-poor 
laboratory. Care should always be paid for counting blasts with the right black color, 
intensely stained granules. The appealing characters that entail the use of SBB stain are: 
i. The reaction and non-reaction with SBB stain are both significant, as the former refer 
practically to AML and the latter supports the diagnosis of ALL or AML-M0. 
ii. The intensity of a positive reaction with SBB in general parallels myeloperoxidase 
activity. Generally local experience would decide which stain to choose. However, SBB 
gives a slightly more intense reaction and sensitivity than myeloperoxidase staining in 
the detection of myeloblasts and is safer than the older technique of MPO staining 
(using carcinogenic benzidine or its derivatives). 
iii. Better demonstration of Auer rods by using SBB stain than any of the usual 
Romanowsky stains. This would be of utmost benefit to identify all MDS cases with 
Auer rods, to differentiate some AML from ALL cases (Image 4) and also to follow up 
AML cases for morphological remission after induction chemotherapy.  
 
 
Image 4. Composite photograph of the peripheral blood film of a patient with AML-M2, the 
blasts showed unusual nuclear lobulation, these blasts contained  SBB positive granules and 
Auer rods (Abdulsalam et al, 2011b) 
In all AML subtypes, except for AML-M3, the presence of even one blast cell with Auer 
rod would refer to failure to achieve remission and indicate the need for a second 
induction chemotherapy course, while in AML-M3 finding an Auer rod after induction 
www.intechopen.com
 Diagnosis of Acute Leukemia in Under-Resourced Laboratories 
 
31 
is usually a part of response to treatment as it appears in more maturing myeloid cells 
(Wong, 2010) (Image 5). 
iv. The presence of 3% or more SBB stain positive blasts would characteristically refer to 
the diagnosis of AML-M1 rather than ALL. 
Although it is now about 30 years since first reporting that in very rare cases even ALL 
blasts may show SBB positivity (Tricota, et al, 1982); however characters like being of 
less intensity than the control (remnant normal cells of the myeloid series), non-
granular and diffuse reaction help to indicate that these are not myeloblasts. Also 
lymphoblasts would universally stain negative with MPO which can then be used to 
confirm the nature of the blasts. 
v. Increased SBB stain positivity at diagnosis is associated with better prognosis. 
vi. Speedy and firm enough diagnosis of AML-M3 variant cases (Image 6) to start ATRA 
treatment in the same day (Abdulsalam & Sabeeh, 2010). 
vii. Demonstration of myeloid series dysplasia (Image 7) (Bain, 2010b). 
viii. The stain can be easily applied to peripheral blood as well as bone marrow aspirate 
smears. 
 
 
Image 5. Peripheral blood film of a patient with AML-M3 on ATRA treatment showing a 
dysplastic neutrophil that contains an Auer rod (Abdulsalam and Sabeeh, 2009b) 
3.11.1.1 How to count the percentage of SBB positively stained blasts 
The literatures are always referring to directly counting the blasts from the SBB stain slide, 
which is the best technique if the blasts can be easily recognized, but in practice and 
especially with AML-M1 this is not always feasible due to the nature of the stain which 
renders many blasts indistinguishable from other less immature cells. Therefore, there 
should be a second best technique to count the percent of smear positive SBB blasts, because 
it is not always possible to differentiate all the blasts directly from the SBB slide. 
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In the author’s hematology laboratory practice the following procedure is applied by first 
utilizing the Leishman stain slide for counting cells into 3 categories as fractions from all the 
total marrow cells: 1st the blast cells; 2nd the maturing myeloid cells, which would be all 
assumed to stain positive, although some may actually be negative as a feature of 
myelodysplasia but nevertheless in calculations this would provide a higher safety 
threshold to avoid inappropriately classifying a case as AML and 3rd category for 
lymphocytes and nucleated red cells, which would be negatively stained. Then from the SBB 
stain slide count all the SBB positive cells and deducing the relative percentage of the SBB 
positive blasts. 
 
 
Image 6. Composite photograph showing Leishman staining (left) and SBB,    
cytochemical, staining (right)  diagnosis of the variant form of AML-M3  (Abdulsalam & 
Sabeeh, 2010). 
3.11.2 NSE 
Including α-naphthyl acetate esterase (ANAE), or preferably, α-naphthyl butyrate esterase 
(ANBE) which is more specific than the acetate stain for the monocytic lineage, either stain 
is required to confirm the morphological diagnosis of AML-M4, M5a and M5b. 
In some occasions there might be a differential diagnosis between M3v and M5b, in which 
cases it is best to avoid discrimination between them based only on NSE as it may be 
positive in both leukemias, instead a strong reaction with SBB in M3v can be used. 
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Image 7. Dysplastic metamyelocyte (bottom right) that is completely agranular with SBB 
staining. {Same patient in Image 4} 
3.11.3 Periodic Acid Schiff (PAS) 
It adds a minor support to diagnosis of ALL as a similar reaction can be seen, although less 
frequently in AML. Although the pattern of reaction was considered important in some 
literatures (Lewis et al, 2006) to differentiate between ALL (with clear cytoplasm between 
the positive granules) and AML (with cytoplasmic smudge positivity between the positive 
granules) but in practice relying on such a difference is very difficult, therefore, PAS use is 
considered non-essential and should be replaced by CD3 and CD79a ICC/IHC. 
The other late advantage of PAS was to refer to possible cases of c-ALL; again this use has 
been superseded by CD10. 
3.12 Immunophenotyping 
Refers to identification of antigens within or on the surface of cells for the purpose of 
lineage assignment. It is not a proof for clonality instead of the genetic study. 
In AML patients it is essential for proper diagnosis of M0 and M7. In ALL it is essential for 
diagnosis and risk stratification including T and B lineage assignment (as there is no reliable 
morphological features to differentiate between them), and subclassification into pro-, 
common (c), pre- and mature B-ALL and early, cortical and mature T-ALL. 
A suggested list of ICC and IHC CD markers that should be available for diagnosis of acute 
leukemia can include: CD3 for T-ALL (CD7 is more sensitive than CD3, it almost reach 100% 
sensitivity for T-ALL but is not specific as it is also positive in 20% of AML cases; however, 
CD7 is still an excellent substitute for T-lineage assignment in rare cases of CD3 negative T-
ALL where with the proper clinical and radiological features, Romanowsky and special 
stains morphology and other CD markers, as negative anti-MPO, then the diagnosis of ALL 
is evident) and CD79a for B-ALL. 
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When B-ALL diagnosis is confirmed then CD20 would help to decide for anti-CD20 
(Rituximab) treatment option. 
 TdT would help to differentiate ALL-L2 (where it is positive) from leukemic phase of 
lymphoma (where it is negative). 
For B-ALL CD10 is negative in pro-B-ALL and positive in common-ALL (c-ALL) which 
confers better prognosis. In pre-B-ALL cytoplasmic immunoglobulin (cIg) is positive while 
surface Ig (sIg) is positive only in mature B-ALL (ALL-L3 or leukemic phase of Burkitt’s 
lymphoma, in which case TdT is negative). 
Only cytoplasmic CD3 (cCD3) is positive in early T-ALL, cCD3 and CD1a are both positive 
in thymic or cortical T-ALL which confers better prognosis, while in mature T-ALL surface 
CD3 (sCD3) is positive and CD1a is negative. 
Anti-myeloperoxidase, CD117 or CD33 can be used for AML-M0 and CD41 for AML-M7. 
The availability of CD45 can be useful in rare occasions to ensure the hemopoietic nature of 
a poorly differentiated malignancy (Bain et al, 2002). 
3.12.1 Flowcytometry 
The newer multicolor (detecting many CD markers in/on the same single malignant cell) 
and multiparametric (a character comparative to that of automated blood counters studying 
characters like cell size and granularity) flowcytometer is one of the ultimate routine 
techniques in diagnosis of AML and ALL, primary risk stratification of ALL and follow up 
for MRD. When there is leucocytosis due to leukemic blasts then the flowcytometry study 
can be done on peripheral blood, otherwise, a bone marrow aspirate is the specimen of 
choice. However, the current price of the flowcytometer, cost of operating kits and 
maintenance make it unsuitable for laboratories with small budget. 
3.12.2 Immunocytochemistry (ICC) 
This technique should be consistently used in resource-poor laboratories for lineage and 
sub-lineage assignment of acute leukemia. It is applied on the bone marrow aspirate smear 
or, less conveniently on the peripheral blood after removal of plasma or on buffy coat (only 
if the blast percent is high). Sample spread can be done on a regular glass-slide (it is not 
essential to use a positively charged slide as in IHC) and after fixation in alcohol, ICC can be 
applied directly or after storage. 
In acute leukemia the results of ICC (Image 8) can be interpreted in much more logical sense 
than IHC as the remaining normal or reactive cells can express some diagnosis-unrelated 
but confusing CD marker that in the aspirate can be easily detected to appear only for non-
blast cells. 
3.12.3 Immunohistochemistry (IHC) 
Can be used as a substitute for ICC as the second best test for immunophenotyping of acute 
leukemia in the resource-poor laboratories if the blast percent is high, and if the results are 
unequivocally positive or negative or when the bone marrow aspirate is inadequate, 
otherwise when the blast percent is low or when the IHC positive result is in the borderline 
zone (20-30%) the judgment on the result of IHC can be difficult. For paraffin embedded 
IHC the designation between marker-positive blasts or reactive cells can be very difficult 
and in almost all conditions the total positivity per all marrow cells is expressed. 
www.intechopen.com
 Diagnosis of Acute Leukemia in Under-Resourced Laboratories 
 
35 
 
 
 
Fig. 8. Composite photograph of the same AML-M1 patient in (Image 2) showing CD 3 
negative blasts (top image) with 28% “uncounted” positive small lymphocytes, and CD20 
negative blasts (bottom image) with 5% “uncounted” positive small lymphocytes. 
3.13 Genetic studies 
Including mainly cytogenetics, InSitu Hybridization (ISH) and PCR. All of these techniques 
have advantages and limitations and the choice in acute leukemia should be based on at 
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least two different techniques that would give complementary information especially for 
risk stratification and follow up for MRD. 
Older techniques, like Feulgen stain for quantization of DNA contents should be avoided 
even in under-resourced laboratories because these techniques are non-standard and 
confusing. 
3.13.1 Cytogenetics 
It should be routinely applied for every suspected case of acute leukemia. Cytogenetics 
would represent to genetic studies what a blood smear represents to hematology, i.e., study 
of morphology of chromosomes and blood cells respectively. However, it has major 
limitations as the procedure-inherent failure rate and inability to detect small size 
aberrations or cryptic translocations. 
Cytogenetics, beside a molecular study, is essential for the application of the WHO 
classification of acute leukemia and its risk stratification. 
3.13.2 InSitu Hybridization (ISH) 
Including Flourescent InSitu Hybridization (FISH) and Chromogenic InSitu Hybridization 
(CISH). Each technique has its advantages and limitations. FISH would represent a 
molecular genetic study plus demonstration of some chromosomal morphology. While 
CISH would represent a molecular genetic study plus demonstration of tissue morphology. 
In the author’s opinion both techniques are not ideal for diagnosis, risk stratification and 
follow up of acute leukemia in an under-resourced laboratory. 
3.13.3 Polymerase Chain Reaction (PCR) 
Using only one detection kit multiplex RT-PCR assay is an effective, sensitive, accurate and 
cost-effective one-step multiple molecular re-arrangements diagnostic and risk-stratification 
tool. It is a complementary technique to conventional cytogenetics for risk stratification of 
acute leukemia and it provides a platform for the later on possibility of RQ-PCR detection of 
minimal residual disease (MRD) as multiplex RT-PCR is a qualitative procedure and is not 
used by itself as a mean for detection of MRD. For ALL, ETV6-RUNX1 and TCF3-PBX1 
(both confer good prognosis), and MLL-MLLt2 and BCR-ABL1 (both confer poor prognosis) 
(Cerveira at al, 2000 and Shai, 2010); and for AML, FLT3 and MLL (both confer poor 
prognosis), and NPM1 and CEBPA (both confer good prognosis) (Strehl et al, 2001) paired 
primers are useful options (Salto-Tellez et al, 2003). 
3.14 Chemotherapeutic trial for acute leukemia 
A chemotherapeutic trial for those who cannot afford to seek a more precise diagnosis with 
genetic study and lineage specification abroad is a realistic option, as the response to 
treatment could be a very useful confirmation of the provisional diagnosis. The two 
examples already the author had faced are AML-M3v diagnosed provisionally only by 
morphology but with a dramatic response to ATRA trial, confirming the diagnosis (Image 9) 
and a few cases of morphologically undifferentiated acute leukemia in which the induction 
therapy for ALL is tried first (using vincristine and prednisolone only). If the patient 
responds, then a diagnosis of ALL can be deduced; if not, the regimen should be shifted to 
chemotherapy of AML (Abdulsalam, 2009). 
www.intechopen.com
 Diagnosis of Acute Leukemia in Under-Resourced Laboratories 
 
37 
 
 
 
 
Image 9. Peripheral blood film showed 94% abnormal granulated promyelocytes. In the 
absence of any specialized tests, the diagnosis was made from cytological features. There 
was a dramatic response to ATRA, confirming the morphological diagnosis of AML-M3v 
(Abdulsalam & Nafila, 2009). 
3.15 Lumbar puncture 
Looking for cerebrospinal fluid (CSF) involvement with acute leukemia is advised in all 
patients with ALL, while for patients with AML it is only indicated for patients with 
neurological symptoms.  
3.16 Remission 
Durable remission in acute leukemia is based on clinical and morphological evidences. 
Clinical remission includes absence of symptoms and signs of leukemia. Complete blood 
count consistent with remission would include absence of severe anemia, neutrophil 
count more than 1 ×109/l and platelet count more than 100 ×109/l (Bain, 2010). 
Morphological remission of acute leukemia from peripheral blood involves absence of 
blasts, immature myeloid cells and nucleated red cells. Bone marrow aspirate consistent 
with morphological remission would include blast cells being less than 5% with absence 
of Auer rods. The presence of even one Auer rod on SBB stain would refer to failure to 
achieve remission. 
Flowcytometry, cytogenetics or molecular genetics may be used to validate a morphological 
remission if any of these techniques were already utilized at diagnosis. 
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3.17 Minimal residual disease (MRD) 
Detection of MRD entails the availability of either RQ-PCR or multi-color flowcytometry. 
Both techniques may not be routinely feasible for a laboratory with poor-resources. 
4. Minimal technical requirements for application of WHO classification of 
acute leukemia 
There should be at least a routine availability of CBC (manual or, preferably, automated), 
peripheral blood and bone marrow aspirate smears (and in some occasions bone marrow 
biopsy), SBB and a NSE stains, immunocytochemistry with/without immunohistochemistry 
(including at least CD3, CD79a, anti-MPO and CD41), cytogenetics and conventional PCR 
for the multiplex primers already mentioned in paragraph 3.13.3. 
5. Conclusion 
In hematology laboratories where the diagnostic resources are limited, it is essential to 
establish local guidelines that are practical in developing cost-effective diagnostic protocols 
for conditions for which the treatment is available, plus leaving the door wide open for 
future improvements, as to the introduction of newer techniques to the already available 
procedures once a newer therapeutic agent with certain lineage assignment demands has 
been introduced. 
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